Page last updated: 2024-08-24

irinotecan and azd 6244

irinotecan has been researched along with azd 6244 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Cohen, D; Cohen, S; Denlinger, C; Gold, PJ; Hochster, HS; Leichman, CG; Leichman, L; Lenz, HJ; Messersmith, W; ONeil, BH; Uboha, N	1
Chawla, SP; Higuchi, T; Hoffman, RM; Hu, K; Kawaguchi, K; Kiyuna, T; Miyake, K; Miyake, M; Oshiro, H; Razmjooei, S; Singh, SR; Wangsiricharoen, S; Zhang, Z	1

Trials

1 trial(s) available for irinotecan and azd 6244

Article	Year
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Early Termination of Clinical Trials; Female; Humans; Irinotecan; Male; MAP Kinase Kinase Kinases; Middle Aged; Mutation; Neoplasm Proteins; Pilot Projects; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Analysis; Topoisomerase I Inhibitors	2015

Article

Year

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.

Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Early Termination of Clinical Trials; Female; Humans; Irinotecan; Male; MAP Kinase Kinase Kinases; Middle Aged; Mutation; Neoplasm Proteins; Pilot Projects; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Analysis; Topoisomerase I Inhibitors

2015

Other Studies

2 other study(ies) available for irinotecan and azd 6244

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations. Scientific reports, 2020, 11-18, Volume: 10, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Body Weight; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms, Experimental; Mice, Nude; Phenylurea Compounds; Proof of Concept Study; Pyridines; Xenograft Model Antitumor Assays	2020

Article

Year

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.

Chemical research in toxicology, 2010, Volume: 23, Issue:1

Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010

A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations.

Scientific reports, 2020, 11-18, Volume: 10, Issue:1

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Body Weight; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms, Experimental; Mice, Nude; Phenylurea Compounds; Proof of Concept Study; Pyridines; Xenograft Model Antitumor Assays

2020